Critical Outcome Technologies Announces Warrant Issuance

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT
INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN
THE UNITED STATES.


Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE:COT),
the bioinformatics and accelerated drug discovery company, announced today that
further to its previously announced engagement (the "Agreement") with Maxim
Group LLC ("Maxim"), the Company has made the first advisory fee payment for
services performed by Maxim under the terms of the Agreement. The Company issued
common share purchase warrants (the "Advisory Warrants") expiring on April 11,
2019 to acquire 1,500,000 common shares of COTI at an exercise price of USD
$0.19 per share. Maxim is eligible to receive up to 3,000,000 Advisory Warrants
issuable over the term of the Agreement for its strategic advisory services.


The exercise price of the Advisory Warrants is calculated based upon the volume
weighted average trading price of the Company's common shares on the TSX Venture
Exchange for the five trading days immediately preceding the date of issue and
is converted to USD at the Bank of Canada closing exchange rate for the date
immediately preceding the date of issue.


The Advisory Warrants and any shares issued upon warrant exercise will be
subject to a hold period related to resale in Canada of four months plus one day
and a hold period in the United States in accordance with applicable securities
laws. 


The securities referred to in this news release have not been, nor will they be,
registered under the United States Securities Act of 1933, as amended, and may
not be offered or sold within the United States or to, or for the account or
benefit of, U.S. persons absent U.S. registration or an applicable exemption
from the U.S. registration requirements. This news release does not constitute
an offer for sale of securities or a solicitation for offers to buy any
securities. Any public offering of securities in the United States must be made
by means of a prospectus containing detailed information about the company and
management, as well as financial statements.


About Critical Outcome Technologies Inc.

COTI is a leading-edge technology company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI's proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective.


Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome.

Notice to Readers

Information contained in this press release may contain certain statements,
which constitute "forward- looking statements" within the meaning of the
Securities Act (Ontario) and applicable securities laws. For example, the
statement "Maxim is eligible to receive up to 3,000,000 Advisory Warrants
issuable over the term of the agreement for its strategic advisory services" is
a forward-looking statement. Forward-looking statements by their nature are not
guarantees of future performance and are based upon management's current
expectations, estimates, projections and assumptions. COTI operates in a highly
competitive environment that involves significant risks and uncertainties, which
could cause actual results to differ materially from those anticipated in these
forward-looking statements. Management of COTI considers the assumptions on
which these forward-looking statements are based to be reasonable, but as a
result of the many risk factors, cautions the reader that actual results could
differ materially from those expressed or implied in these forward-looking
statements. Information in this press release should be considered accurate only
as of the date of the release and may be superseded by more recent information
disclosed in later press releases, filings with the securities regulatory
authorities or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
wdanter@criticaloutcome.com
www.criticaloutcome.com


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
trevor@heislercommunications.com
Cotinga Pharmaceuticals (TSXV:COT)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024